Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Operating Expenses (2017 - 2025)

UroGen Pharma (URGN) has disclosed Operating Expenses for 9 consecutive years, with $53.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 7.86% year-over-year to $53.7 million, compared with a TTM value of $222.2 million through Dec 2025, up 24.62%, and an annual FY2025 reading of $222.2 million, up 24.62% over the prior year.
  • Operating Expenses was $53.7 million for Q4 2025 at UroGen Pharma, up from $51.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $62.1 million in Q2 2025 and bottomed at $32.0 million in Q3 2023.
  • Average Operating Expenses over 5 years is $40.5 million, with a median of $36.0 million recorded in 2022.
  • The sharpest move saw Operating Expenses dropped 15.19% in 2021, then skyrocketed 38.77% in 2024.
  • Year by year, Operating Expenses stood at $34.5 million in 2021, then increased by 4.67% to $36.1 million in 2022, then decreased by 0.71% to $35.9 million in 2023, then surged by 38.77% to $49.8 million in 2024, then rose by 7.86% to $53.7 million in 2025.
  • Business Quant data shows Operating Expenses for URGN at $53.7 million in Q4 2025, $51.6 million in Q3 2025, and $62.1 million in Q2 2025.